Combined Analysis of CSF Tau, Aβ42, Aβ1–42% and Aβ1–40ox% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia

Combined Analysis of CSF Tau, Aβ42, Aβ1–42% and Aβ1–40ox% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia

We studied the diagnostic value of CSF Aβ42/tau versus low Aβ1–42% and high Aβ1–40ox% levels for differential diagnosis of Alzheimer's disease (AD) and dementia with Lewy bodies (DLB), respectively. CSF of 45 patients with AD, 15 with DLB, 21 with Parkinson's disease dementia (PDD), and 40...

Full description

Bibliographic Details
Main Authors:	Mirko Bibl, Hermann Esselmann, Piotr Lewczuk, Claudia Trenkwalder, Markus Otto, Johannes Kornhuber, Jens Wiltfang, Brit Mollenhauer
Format:	Article
Language:	English
Published:	Hindawi Limited 2010-01-01
Series:	International Journal of Alzheimer's Disease
Online Access:	http://dx.doi.org/10.4061/2010/761571

Similar Items

Abnormal CSF amyloid-β42 and tau levels in hip fracture patients without dementia.
by: Esther S Oh, et al.
Published: (2018-01-01)

Correction: Abnormal CSF amyloid-β42 and tau levels in hip fracture patients without dementia.
by: PLOS ONE Staff
Published: (2018-01-01)

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
by: Oskar Hansson, et al.
Published: (2019-04-01)

A Specific Reduction in Aβ1−42 vs. a Universal Loss of Aβ Peptides in CSF Differentiates Alzheimer's Disease From Meningitis and Multiple Sclerosis
by: Philipp Spitzer, et al.
Published: (2018-05-01)

Differential role of CSF alpha-synuclein species, tau and Aβ42 in Parkinson’s Disease
by: Lucilla eParnetti, et al.
Published: (2014-03-01)

CSF sTREM2 in delirium—relation to Alzheimer’s disease CSF biomarkers Aβ42, t-tau and p-tau
by: Kristi Henjum, et al.
Published: (2018-11-01)

Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts
by: Lih-Fen Lue, et al.
Published: (2017-07-01)

CSF Potential Biomarkers Aβ42 and Tau: associations of Apo E Genotype
by: Gill KD, et al.
Published: (2010-04-01)

CSF T-Tau/Aβ42 predicts white matter microstructure in healthy adults at risk for Alzheimer's disease.
by: Barbara B Bendlin, et al.
Published: (2012-01-01)

Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid β(1-42), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop
by: Charlotte E. Teunissen, et al.
Published: (2010-01-01)

Aggregation and Fibril Structure of AβM01-42 and Aβ1-42
by: Frederick, Kendra K., et al.
Published: (2018)

Diagnostic Utility of Selected Serum Dementia Biomarkers: Amyloid β-40, Amyloid β-42, Tau Protein, and YKL-40: A Review
by: Karolina Wilczyńska, et al.
Published: (2020-10-01)

Dynamic Blood Concentrations of Aβ1–40 and Aβ1–42 in Alzheimer’s Disease
by: Yuan-Han Yang, et al.
Published: (2020-08-01)

Genome-wide network-based pathway analysis of CSF t-tau/Aβ1-42 ratio in the ADNI cohort
by: Wang Cong, et al.
Published: (2017-05-01)

Aβ and tau structure‐based biomarkers for a blood‐ and CSF‐based two‐step recruitment strategy to identify patients with dementia due to Alzheimer's disease
by: Andreas Nabers, et al.
Published: (2019-12-01)

Alterations of CSF cystatin C levels and their correlations with CSF Αβ40 and Αβ42 levels in patients with Alzheimer's disease, dementia with lewy bodies and the atrophic form of general paresis.
by: Xiao-Mei Zhong, et al.
Published: (2013-01-01)

Reduced CSF turnover and decreased ventricular Aβ42 levels are related
by: Jouanny Pierre, et al.
Published: (2011-05-01)

Patients with mild cognitive impairment and a reduced CSF Aβ1-42 protein progress rapidly to Alzheimer's disease
by: J.A. Monge-Argilés, et al.
Published: (2012-01-01)

The combined effect of amyloid-β and tau biomarkers on brain atrophy in dementia with Lewy bodies
by: Carla Abdelnour, et al.
Published: (2020-01-01)

Microarray analysis on human neuroblastoma cells exposed to aluminum, β(1-42)-amyloid or the β(1-42)-amyloid aluminum complex.
by: Valentina Gatta, et al.
Published: (2011-01-01)

A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer’s disease
by: Hedieh Shahpasand-Kroner, et al.
Published: (2018-12-01)

Frontotemporal dementia is the leading cause of “true” A−/T+ profiles defined with Aβ42/40 ratio
by: Hélène Pouclet‐Courtemanche, et al.
Published: (2019-12-01)

Derivation of cutoffs for the Elecsys® amyloid β (1–42) assay in Alzheimer's disease
by: Leslie M. Shaw, et al.
Published: (2018-01-01)

Aggregation states of Aβ1-40, Aβ1-42 and Aβp3-42 amyloid beta peptides: a SANS study
by: Festa, Giulia, et al.
Published: (2020)

A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid.
by: Niels Kruse, et al.
Published: (2016-01-01)

Prognostic Role of CSF β-amyloid 1–42/1–40 Ratio in Patients Affected by Amyotrophic Lateral Sclerosis
by: Tiziana Colletti, et al.
Published: (2021-02-01)

Mechanism of neurotoxicity of Aβ42 peptide in Alzheimer's disease
by: Murakami, Kazuma
Published: (2011)

Protection of TGF-β1 against neuroinflammation and neurodegeneration in Aβ1-42-induced Alzheimer's disease model rats.
by: Jia-Hui Chen, et al.
Published: (2015-01-01)

AβPP processing results in greater toxicity per amount of Aβ1-42 than individually expressed and secreted Aβ1-42 in Drosophila melanogaster
by: Liza Bergkvist, et al.
Published: (2016-08-01)

Aβ43 in human Alzheimer’s disease: effects of active Aβ42 immunization
by: Lieke Jäkel, et al.
Published: (2019-09-01)

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
by: Inger van Steenoven, et al.
Published: (2019-10-01)

Cerebrospinal fluid β-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies
by: L. Parnetti, et al.
Published: (2009-06-01)

The nonlinear relationship between cerebrospinal fluid Aβ42 and tau in preclinical Alzheimer's disease.
by: Mony J de Leon, et al.
Published: (2018-01-01)

Mechanistic Investigation of the Inhibition of Aβ42 Assembly and Neurotoxicity by Aβ42 C-terminal Fragments
by: Li, Huiyuan, et al.
Published: (2013)

CSF Aβ1–42 level is associated with cognitive decline in early Parkinson’s disease with rapid eye movement sleep behavior disorder
by: Maowen Ba, et al.
Published: (2018-10-01)

The Aβ(1–38) peptide is a negative regulator of the Aβ(1–42) peptide implicated in Alzheimer disease progression
by: Maa O. Quartey, et al.
Published: (2021-01-01)

In vitro fibrillization of Alzheimer’s amyloid-β peptide (1-42)
by: Ann Tiiman, et al.
Published: (2015-09-01)

Synergistic Effect on Neurodegeneration by N-Truncated Aβ4−42 and Pyroglutamate Aβ3−42 in a Mouse Model of Alzheimer's Disease
by: Jose S. Lopez-Noguerola, et al.
Published: (2018-03-01)

TGF-β1 Protection against Aβ1–42-Induced Neuroinflammation and Neurodegeneration in Rats
by: Wei-Xing Shen, et al.
Published: (2014-12-01)

Cathepsin D regulates cerebral Aβ42/40 ratios via differential degradation of Aβ42 and Aβ40
by: Caitlin N. Suire, et al.
Published: (2020-07-01)